GSK and CHK1 no go14 Oct 2022 22:05
GSK’s anti-TIM-3 antibody is moving into a pivotal trial after hitting the mark in the midphase portion of the study, cementing the Big Pharma’s status as a front-runner in a thinning field featuring Novartis.
TIM-3 is a checkpoint receptor and the latest in a series of targets that have caught the imagination of the immuno-oncology sector. With interest in TIGIT, another checkpoint receptor, on the rocks after the failure of Roche’s candidate, TIM-3 lung cancer trial could now step into the limelight. But companies still need to deliver data to show it can avoid the doomed fates of previous red-hot immuno-oncology targets.
GSK took a step toward potentially validatory data Wednesday, revealing that both arms of its phase 2/3 non-small cell lung cancer (NSCLC) clinical trial have met the criteria for advancing into the next stage of the study.
Patients in one of the arms received the anti-TIM-3 antibody cobolimab, GSK’s PD-1 checkpoint inhibitor Jemperli and the chemotherapy docetaxel. Participants in the second cohort only received Jemperli and docetaxel, while a third group is receiving docetaxel as a monotherapy to serve as the active control arm.
GSK is yet to post data from the phase 2 portion of the trial. But, with the data clearing the pre-specified expansion criteria, the two arms are moving into the phase 3 portion of the study…
Most likely the reason as to why GSK/Sierra returned SRA737.
Plenty of hype. Cleared the bar. Basically means it has passed the minimum criteria set. I am of the opinion by their positive slant that it may not be as good as is made out. Look out for adverse side effects later down the line. Stage 3 coming of course and it has to out perform what is currently used in the market place.
SRA737 been sat on for the past 2 years. Would have been very interesting in a direct comparison of the 2.
Lots to go for for GSK.
SRA737 formerly CCT245737.
Bare in mind there has never been a CHK1 inhibitor approved for clinical use.
Not overly effective on its own.
Low to medium toxicity and side effects.
Improves the potency of LDG and when used in combination each can be used at much lower dosages.
CHK1, LDG and a PD-1 inhibitor. Phenomenal results in Lung cancer.
Ovarian cancer will cause problems with CHK1 inhibitors as will evade the P53 target checkpoint.
Recently heavily researched and found that these alternative pathways can be blocked by an inhibitor. Alternative pathways are PI-3K and ATK. There are inhibitors that will block these signalling pathways. These inhibitors have been approved for clinical use.
Further down the line you have immunotherapy drugs.
It is worth noting here that in the patent for SDC1802, the description allows for 1802 to be used in combo with many other forms of treatment ( primarily kinase inhibitors)
It can be used in conjunction with gemcitabine for the purpose of reversing or reinstalling potency, via the inhibiting of the resistance by the canc
Sign In
Follow the stocks
